• 1. Howell, C. R., Zhang, L., Yi, N., Mehta, T., Garvey, W. T., & Cherrington, A. L. (2022). Race versus social determinants of health in COVID-19 hospitalization prediction. American Journal of Preventive Medicine, 63(1 Suppl 1), S103-S108. https://doi.org/10.1016/j.amepre.2022.01.034
• 2. Garvey, W. T., & Mechanick, J. I. (2022). Cardiometabolic disease: Insulin resistance, obesity, and the metabolic syndrome. In V. Fuster, J. Narula, P. Vaishnava, M. B. Leon, D. J. Callans, J. S. Rumsfeld, et al. (Eds.), Fuster and Hurst’s The Heart (15th ed.). New York, NY: McGraw-Hill Education. Retrieved July 18, 2024, from https://accessmedicine.mhmedical.com/content.aspx?aid=1205976467
• 3. Garvey, W. T. (2023). The fundamental role of obesity management in cardiometabolic risk reduction: Nonpharmacological, pharmacological, and surgical approaches. In A. J. Krentz & R. J. Chilton (Eds.), Cardiovascular endocrinology and metabolism (pp. 273-309). Academic Press. https://www.sciencedirect.com/science/article/pii/B9780323999915000188
• 4. Howell, C. R., Zhang, L., Mehta, T., Wilkinson, L., Carson, A. P., Levitan, E. B., Cherrington, A. L., Yi, N., & Garvey, W. T. (2024). Cardiometabolic disease staging and major adverse cardiovascular event prediction in 2 prospective cohorts. JACC: Advances, 3(4), 100868. https://doi.org/10.1016/j.jacadv.2024.100868
• 5. Garvey, W. T. (2024). Lifestyle medicine: Closing research practice and knowledge gaps. Forthcoming.
• 6. Howell, C. R., Zhang, L., Yi, N., Mehta, T., Cherrington, A. L., & Garvey, W. T. (2022). Associations between cardiometabolic disease severity, social determinants of health (SDoH), and poor COVID-19 outcomes. Obesity, 30(7), 1483-1494. https://doi.org/10.1002/oby.23440
• 7. Wilkinson, L., Yi, N., Mehta, T., Judd, S., & Garvey, W. T. (2020). Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study. PLOS Medicine, 17(8), e1003232. https://doi.org/10.1371/journal.pmed.1003232
• 8. Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M. I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Basora, J., Muñoz, M. A., Sorlí, J. V., Martínez, J. A., & Martínez-González, M. Á. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. The New England Journal of Medicine, 368(14), 1279-1290. https://doi.org/10.1056/NEJMoa1200303
• 9. Garvey, W. T. (2022). New horizons: A new paradigm for treating to target with second-generation obesity medications. The Journal of Clinical Endocrinology & Metabolism, 107(4), e1339-e1347. https://doi.org/10.1210/clinem/dgab891
• 10. Mechanick JI, Hurley DL, Garvey WT. Adiposity-Based Chronic Disease as a New Diagnostic Term: American Association of Clinical Endocrinologists and the American College of Endocrinology Position Statement. Endocr Pract. 2017 Mar;23(3):372-378. doi: 10.4158/EP161688.PS.
• 11. Frühbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J, Halford JGC, Farpour-Lambert NJ, Blaak EE, Woodward E, Toplak H. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts. 2019;12(2):131-136. doi: 10.1159/000497124.
• 12. Arnett DK et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol 2019;74(10):e177-e232
• 13. Eckel RH et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am Coll Cardiol 2014;63(25 Pt B):2960-2984
• 14. Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, Mitri J, Pereira RF, Rawlings K, Robinson S, Saslow L, Uelmen S, Urbanski PB, Yancy WS Jr. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019; 42(5):731-754
• 15. Tham KW, Abdul Ghani R, Cua SC, Deerochanawong C, Fojas M, Hocking S, Lee J, Nam TQ, Pathan F, Saboo B, Soegondo S, Somasundaram N, Yong AML, Ashkenas J, Webster N, Oldfield B. Obesity in South and Southeast Asia-A new consensus on care and management. Obes Rev. 2023 Feb;24(2):e13520. doi: 10.1111/obr.13520. Epub 2022 Dec 1. PMID: 36453081; PMCID: PMC10078503.
• 16. Wilkinson L, Yi N, Mehta T, Judd S, Garvey WT. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study. PLoS Med. 2020 Aug 7;17(8):e1003232. doi: 10.1371/journal.pmed.1003232. Erratum in: PLoS Med. 2023 Mar 30;20(3):e1004217. doi: 10.1371/journal.pmed.1004217. PMID: 32764746; PMCID: PMC7413417.
• 17. Wilkinson L, Holst-Hansen T, Laursen PN, Rinnov AR, Batterham RL, Garvey WT. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. Obesity (Silver Spring). 2023 Sep;31(9):2249-2259. doi: 10.1002/oby.23842. PMID: 37605636.
• 18. Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Stefanski A, Garvey WT. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial. Diabetes Obes Metab. 2023 Dec;25(12):3748-3756. doi: 10.1111/dom.15269. Epub 2023 Sep 12. PMID: 37700443.
• 19. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. PMID: 28437620.